ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2020
Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- The efficacy and safety of acupuncture for Parkinson's disease insomnia: a systematic review and meta-analysis.Frontiers in neurology · 2025Pooled it
- Daily-Life, Sensor-Derived Tremor Measures Are Sensitive to Progression in Early Parkinson's Disease.Annals of neurology · 2026Article
- Disease-Duration-Specific Percentiles for Prospective Subtyping of Parkinson's Disease: A PPMI-Based Study.Movement disorders clinical practice · 2026Article
- Disease modification in advanced Parkinson's disease: a review and roadmap for paving the way for next-generation interventions.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Multi-Target Neuroprotective Compound Exhibits EAAT2-Modulating and Alzheimer's Pathology-Attenuating Effects in In Vitro and In Vivo Models.ACS chemical neuroscience · 2026Article
- Intake of Folate, Vitamin B6, and Vitamin B12 Before and After Disease Diagnosis and the Risk of Death in Individuals with Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Beyond Pathology: α-Synuclein Homeostasis and Three Principles to Guide Research.Movement disorders clinical practice · 2026Article
- Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson's disease.Journal of neurology · 2026Article
- Osmotin-derived 9-amino-acid peptide alleviates α-synuclein and MPTP-induced glial cell activation mediated neuroinflammation, protecting dopaminergic neurons in Parkinson's disease mice brain.Journal of biomedical science · 2026Article
- Editorial: Parkinson's disease: current findings and challenges in diagnosing and treating motor and non-motor symptoms.Frontiers in aging neuroscience · 2026Article
- Identifying and predicting fast versus slow Parkinson's disease motor progressors using clinical and digital data.BMJ neurology open · 2026Article
- Plasma Metabolomics Profiles in Prodromal and Clinical Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Healthcare Complexities in Neurodegenerative Proteinopathies: A Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
- The Search for Disease Modification in Parkinson's Disease-A Review of the Literature.Life (Basel, Switzerland) · 2025Review
- Identifying Individuals in the Prodromal Phase of Parkinson's Disease: A Prospective Cohort Study.Annals of neurology · 2025Article
- Tetramethylpyrazine nitrone exerts neuroprotection via activation of PGC-1α/Nrf2 pathway in Parkinson's disease models.Journal of advanced research · 2024Article
- The potential role of CGRP in synuclein-associated neurodegenerative disorders.Frontiers in neuroscience · 2024Article
- Aqueous extract ofFrontiers in neuroscience · 2024Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Despite many clinical trials over the last three decades, the goal of demonstrating that a treatment slows the progression of Parkinson's disease (PD) remains elusive. Research advances have shed new insight into cellular pathways contributing to PD pathogenesis and offer increasingly compelling therapeutic targets. Here we review recent and ongoing clinical trials employing novel strategies toward disease modification, including those targeting alpha-synuclein and those repurposing drugs approved for other indications. Active and passive immunotherapy approaches are being studied with the goal to modify the spread of alpha-synuclein pathology in the brain. Classes of currently available drugs that have been proposed to have potential disease-modifying effects for PD include calcium channel blockers, antioxidants, anti-inflammatory agents, iron-chelating agents, glucagon-like peptide 1 agonists, and cAbl tyrosine kinase inhibitors. The mechanistic diversity of these treatments offers hope, but to date, results from these trials have been disappointing. Nevertheless, they provide useful lessons in guiding future therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.